Coca-Cola Europacific Partners: Solid Profit Execution, But Volume Story Keeps Me On The Sidelines

Coca-Cola Europacific Partners (NYSE: CCEP) released its H1 2026 results today and the headline is split. Diluted EPS came in at 2.45 USD per share, edging ahead of the consensus estimate of $2.40. But half-year revenue of 12.48 B USD just missed the $12.54 billion street expected. That is not the kind of dual print that moves the needle decisively one way or the other - and it is not the kind of print that convinces me to buy a stock that has fallen roughly 17% from its May 2026 high of $109.82.

CCEP trades at $91.45 today, sitting in the middle of its 52-week range and above its 200-day moving average. The stock has a market cap of roughly $41.52B. For context, parent company The Coca-Cola Company (KO) trades at 26.1 times trailing earnings with a 2.4% dividend yield. CCEP's own trailing dividend yield is about 2.1%, with a payout ratio that has settled around 48% - well below the 50% target management has maintained. The valuation looks like a discount to parent, but the question is whether that discount is deserved or whether the operating story warrants patience rather than conviction.

The H1 2026 EPS beat is small but real. Earnings per share of $2.45 versus the $2.40 estimate is a 2.12% surprise. Net income for the half year came to 1.20 B USD, up from $997 million in the prior-year period - roughly a 20% year-over-year increase. That profit growth is the bright side of this report and reflects the operating leverage CCEP has been building through its multi-year productivity programs.

The revenue side is less convincing. H1 revenue of $12.48 billion came in slightly below the $12.54 billion consensus. It is a narrow miss, but it is a miss. In a business where management has guided for only 3% to 4% full-year revenue growth, top-line execution matters. Missing consensus in the first half of a year with that narrow growth target puts H2 on the hook. The company would need to deliver essentially in-line or slightly above to stay within its full-year range.

What the H1 2026 numbers tell us

Zooming back to Q1 2026, which sets the first half's opening tone, the picture is mixed. Revenue was €5,001m, up 6.7% as reported and 9.4% on a currency-neutral basis. But a material part of that volume growth came from calendar effects - six additional consumption days versus the prior year. On a comparable basis, group volume grew just 1.6%, with Europe at +1.4% and Asia-Pacific South (APS) at +1.9%. Revenue per unit case rose a modest 0.8% year-over-year.

That is execution, but it is not acceleration. It is the kind of incremental growth that supports a defensive consumer staples name, not the kind that justifies paying up.

The categories that carry the story

CCEP's category breakdown tells a familiar tale. Coca-Cola trademark volumes grew 0.7% in Q1, flavours and mixers added 1.2%, and water, sports, RTD tea and coffee came in at 1.7%. The real engine was the "other including energy" segment, which grew 9.2%. Energy drinks continue to be the growth category in this portfolio, consistent with the double-digit growth CCEP delivered in H1 2025.

Zero-sugar beverages are also performing. The parent company reported strong results for Coca-Cola Zero Sugar, and CCEP management highlighted zeros as a strength in the Q1 update. The structural shift toward sugar-free drinks is real and durable - but it is also priced into the stock. The investor who bought CCEP two years ago on the zero-sugar thesis has already been rewarded.

Guidance, cash flow, and shareholder returns

Management did not change its FY26 guidance, which remains at revenue growth of 3% to 4%, operating profit growth of approximately 7%, and comparable free cash flow of at least €1.7bn. That guidance is H2-weighted, as is typical for CCEP's seasonal profile. The interim dividend for the first half is €0.82 per share (roughly $0.96 in dollar terms), and the company continues its €1 billion share buyback program, with €500m already completed as of the Q1 update.

Full-year 2025 set a solid base: comparable free cash flow of €1,836 million, operating profit of €2,808 million (up 7.5% adjusted comparable), and revenue of €20,901 million. The €4.2 billion EBITDA run rate translates to an EBITDA margin of about 17.81%.

The cash return profile - dividend plus buybacks - is a genuine anchor. At a 2.1% dividend yield plus ongoing repurchases, CCEP is returning meaningful capital to shareholders. That is not a reason to buy a stock on its own, but it is a reason not to panic when the top-line growth story is incremental.

Valuation versus peers

CCEP trades at a discount to parent KO, which sits at 26.1 times trailing earnings. That multiple gap has existed for years, partly because CCEP carries more geographic and operational risk across its 31 markets, and partly because bottler economics - margin compression, input cost volatility, currency exposure - are less pristine than the concentrate model KO operates.

The current CCEP price of $91.45 puts the stock roughly 17% below its May high. That selloff has narrowed the valuation gap, but it has not closed it. At $91, the stock is not screamingly cheap. It is in a zone where the business needs to execute its guidance to justify holding. A miss on H2 volume or operating profit would make the case much harder.

What would change my mind

I would upgrade to Buy if CCEP delivered H2 volume growth meaningfully above the 1.6% pace from Q1, particularly in Europe, where the broader consumer environment remains soft. A surprise on the operating profit side - anything above the ~7% guided rate - would show margin acceleration beyond the current productivity trajectory.

Conversely, I would consider reducing exposure if H2 volumes slip below 1% on a comparable basis or if revenue misses guidance for a second consecutive period. The Suntory alcohol exit, which hit group revenue by approximately 0.5% on an annualized basis, is a one-time drag. But if broader cost-of-sales pressures outpace the ~1.5% per-unit-case increase management expects, the operating profit guidance becomes vulnerable.

Bottom line

CCEP is a well-run bottler with pricing power, a cash-generative balance sheet, and a shareholder return program that works. The H1 2026 results show that profit growth is intact - EPS beat, net income up roughly 20% year over year - but the revenue miss and incremental volume growth keep this in a Hold lane. The 17% selloff from May has improved the risk/reward, but it has not created the kind of valuation reset that demands action.

The catalyst clock points to the Q3 trading update and full-year H2 results later this year. If CCEP hits or beats its 3-4% revenue and ~7% operating profit guidance, the current price becomes more attractive. Until then, patience is the right posture.

Rating: Hold. The business is solid, the guidance is achievable, and shareholder returns provide a floor. But volume growth is not yet compelling enough to justify adding at $91.

Disclosure: This analysis is based on publicly available H1 2026 results, Q1 2026 trading update, and full-year 2025 data. I have no positions in CCEP or KO.